Ferrochelatase (protoheme ferro-lyase, EC 4.99.1.1) catalyzes the last step in the heme biosynthetic pathway, the chelation of ferrous iron and protoporphyrin to form heme. The activity of ferrochelatase is deficient in the inherited disease protoporphyria. In this study, murine ferrochelatase cDNAs were obtained by screening cDNA libraries with an oligonucleotide probe. The derived amino acid sequence of murine ferrochelatase has 47% identity with the recently cloned Saccharomyces cerevisiae ferrochelatase, but it is not significantly similar to other published sequences. Results of Southern blotting are consistent with a single murine ferrochelatase gene, while Northern blotting demonstrates two ferrochelatase transcripts in all tissues examined. The ferrochelatase protein and mRNAs have different relative concentrations in different tissues. The cloning of murine ferrochelatase cDNAs provides the basis for future studies on ferrochelatase gene expression and on the identification of the molecular defect in protoporphyria.Ferrochelatase (also called heme synthetase) (protoheme ferro-lyase, EC 4.99.1.1) catalyzes the last step in the heme biosynthetic pathway, the chelation of ferrous iron and protoporphyrin to form heme. Ferrochelatase is a mitochondrial protein with its active site facing the mitochondrial matrix (1). Ferrochelatase has been characterized and purified to homogeneity from a variety of sources, including the bacteria Spirillum itersonii (2) and Rhodopseudomonas sphaeroides (3); the yeast Saccharomyces cerevisiae (4); rat (5), human (6), bovine (7), mouse (8), and pig (9) liver; chicken erythrocytes (10); bovine kidney (11); and mouse erythroleukemia cells (11). Recently, the gene for ferrochelatase in S. cerevisiae has been cloned (12).The heme biosynthetic pathway is present in all cells in order to provide heme for essential proteins such as respiratory cytochromes. The activity of these heme biosynthetic enzymes is highest in the liver (for synthesis of cytochrome P450) and in erythropoietic tissue (for synthesis of hemoglobin). The regulation of the pathway appears to be different in these two tissues. In the liver, 8-aminolevulinic acid synthase (the first enzyme) is rate limiting and under negative feedback regulation by the end product, heme. In erythroid cells, ferrochelatase appears to be the rate-limiting enzyme (13).The enzymatic activity of ferrochelatase is reduced to 15-25% of normal in all tissues of patients with protoporphyria (14-17). Protoporphyria is an autosomal dominant disease that is characterized biochemically by elevated protoporphyrin levels and clinically by photosensitivity and hepatobiliary disease (18). A rare but severe clinical sequela of protoporphyria is liver failure, leading to orthotopic liver transplantation or death (19-21). There is also an inherited bovine protoporphyria in which the clinical, biochemical, and enzymatic manifestations are similar to the human disease (22,23). Although the deficient ferrochelatase activity is an inherited defect,...